MAP Pharmaceuticals Inc. and Allergan Inc. will collaborate on marketing MAP's Levadex, a self-administered, orally inhaled therapy for acute migraine in adults. MAP, of Mountain View, Calif., will get $60 million up-front and as much as $97 million if it meets milestones.